Results 251 to 260 of about 472,035 (296)

Pharmacologic Prevention of Skeletal-Related Events in Cancer Patients

Orthopedics, 2010
Intravenous bisphosphonates are a standard therapeutic option in the prevention of skeletal-related events in metastatic breast and prostate cancer as well as multiple myeloma with bone involvement. Denosumab represents a new class of medications that inhibits the RANK ligand and is currently being evaluated to prevent skeletal-related events.
Sal, Bottiglieri, Val, Adams, Kelly M, Smith   +2 more
openaire   +2 more sources

Beyond Skeletal-Related Events

European Urology Supplements, 2006
Abstract Objectives Zoledronic acid may have potential antitumor activity; it is the most active agent among the bisphosphonates in blocking the prenylation (activation) of small signaling proteins required for cell function and survival. This presentation discusses the results of preclinical studies evaluating the antitumor activity of zoledronic ...
openaire   +2 more sources

Predicting Skeletal-related Events Using SINS

Spine
Study Design. Predictive study utilized retrospectively collected data. Objective. The primary objective was to evaluate the predictive association between the Spine Instability Neoplastic Score (SINS) and Skeletal-related events (SREs).
Kazuo, Nakanishi, Yasukazu, Hijikata, Kazuya, Uchino, Yoshihisa, Sugimoto, Hideaki, Iba, Seiya, Watanabe, Shigeru, Mitani   +6 more
openaire   +2 more sources

The Pharmacological Management of Skeletal-Related Events From Metastatic Tumors

Orthopedics, 2009
Bone is one of the most common sites of metastatic disease from cancer, affecting around 400,000 patients each year. Skeletal-related events (SRE) include hypercalcemia, fractures, spinal cord compression or severe bone pain and may occur as a complication of metastasis.
Anna, Hitron, Val, Adams
openaire   +2 more sources

Managing skeletal related events resulting from bone metastases

BMJ, 2008
#### Summary points Pain is one of the most common symptoms managed in a palliative setting, and over half of all metastatic cancers will be associated with pain originating from bone metastases. Breast, lung, and prostate cancers account for about 80% of all bone metastases.1 Management of bone pain is especially important in patients with prostate ...
Anna N, Wilkinson, Raymond, Viola, Michael D, Brundage   +2 more
openaire   +2 more sources

Update on the Pharmacological Prevention of Skeletal-related Events in Cancer Patients

Orthopedics, 2011
Metastases to the bone are a frequent complication of advanced cancer. Bone metastases have been linked to skeletal-related events, which is the composite endpoint used in clinical trials evaluating therapy to minimize these complications. This article discusses bisphosphonates, which are the historical standard for the prevention of skeletal-related ...
Kenneth, Kennedy, Hetalkumari, Patel
openaire   +2 more sources

Impact of denosumab on skeletal-related events in solid tumors.

Journal of Clinical Oncology, 2018
e18754Background: Skeletal-related events (SRE) are frequent consequences of bone metastases from solid tumours like breast, prostate and lung.
Sridevi Rajeeve, Stuthi Perimbeti, Karan Jatwani, Rishi Shrivastav, Vivek Modi   +4 more
openaire   +1 more source

Skeletal-Related Events In Myeloma: A Population-Based Study

Blood, 2013
Abstract Introduction New therapies have resulted in improvements in myeloma survival, with increasing numbers of patients receiving treatment over several years. Despite this progress, the remitting and relapsing course of the disease continues to be associated with increases in patient morbidity and
John Ashcroft, Bagguley Timothy, Alexandra Smith, Han-I Wang, Debra Howell, Hazem A Sayala, Gordon Cook, Andrew Jack, Russell Patmore, Eve Roman   +9 more
openaire   +1 more source

Impact of skeletal-related events on multiple myeloma treatment.

Journal of Clinical Oncology, 2018
e20009Background: Skeletal-related events (SREs), sequelae of bone lesions, are common and devastating complications in patients with multiple myeloma (MM).This study assessed the impact of SREs on...
Debajyoti Bhowmik, Nianwen Shi, Janna Manjelievskaia, Xue Song, Sarah Vidito, Michele Intorcia   +5 more
openaire   +1 more source

Analysis of skeletal-related events in breast cancer and response to therapy

Seminars in Oncology, 2001
The skeleton is a common site for the spread of metastatic cancer and skeletal complications are a cause of significant morbidity and mortality. Treatment of skeletal morbidity is therefore an essential component of therapy for cancer patients with bone metastases. Bisphosphonates are currently the treatment of choice for skeletal complications.
openaire   +2 more sources